Home Biological science OMass establishes a scientific advisory board of major

OMass establishes a scientific advisory board of major



OMass Establishes a scientific advisory board made up of leading experts in the use of Biophysical approaches to drug discovery

BeefFord, UUK – March 7 2022 OMass Therapeutics (“OMass” or “the Company”), a biotechnology company identifying drugs against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the creation of its Scientific Advisory Board (SAB) , composed of world-renowned experts across biophysical technologies.

The company’s new SAB will guide OMass’ mission to improve the lives of patients with orphan or immunological diseases through the development of new, differentiated small molecules against hard-to-treat targets. SAB members will help ensure that OMass continues to use and develop its drug discovery platform to its full potential.

The SAB will be led by Professor DI am carol robinson, who founded OMass and is currently a non-executive director and advisor. Carol is widely regarded for her contribution to the field of native mass spectrometry, taking the power and resolution of a highly regarded established technology and applying it to the questioning of biology itself.

The members of the Scientific Council are as follows:

Caroline Robinson is Dr. Lee’s Professor of Chemistry, Founding Director of the Kavli Institute for Nanoscience Discovery in Oxford and Founder of OMass Therapeutics. She was appointed Dame Commander of the Order of the British Empire in 2013 for her contributions to the field of mass spectrometry and research into the 3D structure of proteins and their complexes. She is a leading expert in the field and before leaving for Oxford University, she became the first female professor of chemistry at the University of Cambridge in 2001. She holds ten honorary degrees and is a Foreign Associate of the National Academy of Sciences USA.

Chas Bountra is Pro-Vice-Chancellor for Innovation and Professor of Translational Medicine at the University of Oxford. He is Director of the Center for Medicines Discovery in the Department of Clinical Medicine at Nuffield and an Associate Member of the Department of Pharmacology. Previously, Chas was Vice President and Head of Biology at GlaxoSmithKline, where he was involved in the delivery of several molecules in late-stage development for gastrointestinal, inflammatory and neuropsychiatric diseases. He was also involved in the launch and development of the first treatment for irritable bowel syndrome.

Fiona Marshall is the Global Head of Discovery, Preclinical and Translational Medicine at MSD and was previously a founding member of Sosei Heptares. Fiona is distinguished for her discoveries in the field of G protein-coupled receptors (GPCRs) and is a leader in the field. She has been recognized for her contribution by numerous awards and is a Fellow of the Royal Society, the Academy of Medical Sciences and an Honorary Fellow of the British Pharmacological Society and the Royal Society of Chemistry.

James Naismith is professor of structural biology at the University of Oxford and director of the Rosalind Franklin Institute. James is an expert in structural biology, combining structural analysis, mechanistic study and the development of new biochemical approaches to answer chemical problems in biology. His research aims to bring about transformative change in the life sciences through interdisciplinary research and technology development which has been recognized with various awards including the Colworth Medal, Corday Morgan Medal, Dextra Medal, Jeremy Knowles Medal and , most recently the Royal Society of Chemistry’s. Tiden award in 2019.

JOhn Yates is Ernest W. Hahn Professor in the Departments of Molecular Medicine and Neurobiology at Scripps Research. He has longstanding expertise in mass spectrometry and protein expression and has received several awards for his contributions to the field. He received the 2019 John B. Fenn Award for Distinguished Contribution to Mass Spectrometry and is the principal inventor of the SEQUEST software for correlating tandem mass spectrometry data to the analysis of protein mixtures. He is also the current EIC at Proteome Research Journal.

Rosamond Deegan, CEO of OMass Therapeutics, commented: “I am delighted to welcome such a valued group to OMass. Each member of the Scientific Advisory Board will bring invaluable knowledge and perspective as we continue to enforce our platform against the best targets for orphan and immunologistical diseases.

Professor Dame Carol RobinsonChairman of the Scientific Advisory Board added:It is a pleasure to have been named Chairman of the OMass Scientific Advisory Board, bringing together a team of world leaders and experts in biophysical approaches to drug discovery. I look forward to working closely with the SAB for expand the capabilities of OMass’ exciting technology platform as it is applied against difficult-to-treat membranes and complex-related targets.


For more information, please contact:

Mass therapy Consilium Strategic Communications
Rosamond Deegan, President and CEO

Telephone: +44 (0) 1235 527589

Email: ros.deegan@omass.com

Sue Charles / Chris Gardner / Kumail Waljee

Telephone: +44 (0)20 3709 5700

Email: omass@consilium-comms.com

About OMass Therapeutics

OMass Therapeutics is a biotechnology company identifying drugs against highly validated target ecosystems such as membrane proteins or intracellular complexes. The company’s unique technology platform includes novel biochemistry techniques, next-generation native mass spectrometry and personalized chemistry. This allows OMass to interrogate not only the target, but also how it interacts with its native ecosystem, regardless of the bewildering complexity of the cell. The result is cellular system fidelity with cell-free precision. OMass is advancing a pipeline of small molecule therapeutics in orphan diseases and immunological conditions, targeting solute carriers, inflammasome complexes and GPCRs.

Based in Oxford, UK, OMass is backed by a syndicate of leading investors, Syncona and Oxford Science Enterprises, having closed a Series A funding round of approximately $60 million.

To learn more, visit www.omass.com. Follow us on LinkedIn and Twitter